Notably, several of these have been validated to prevent or arrest diabetes in NOD mice (imatinib, histone deacetylase (HDAC) inhibitors) or to improve c-peptide levels in children with recent-onset T1D and delay the onset of T1D in glucose-intolerant high-risk subjects (cyclosporine). This evidence concerns the gene HDAC9 and diabetes mellitus.